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ABSTRACT
Axolotls are unique among vertebrates in their ability to regenerate
tissues, such as limbs, tail and skin. The axolotl limb is the most
studied regenerating structure. The process is well characterized
morphologically; however, it is not well understood at the molecular
level. We demonstrate that TGF-β1 is highly upregulated during
regeneration and that TGF-β signaling is necessary for the
regenerative process. We show that the basement membrane is not
prematurely formed in animals treated with the TGF-β antagonist SB-
431542. More importantly, Smad2 and Smad3 are differentially
regulated post-translationally during the preparation phase of limb
regeneration. Using specific antagonists for Smad2 and Smad3 we
demonstrate that Smad2 is responsible for the action of TGF-β during
regeneration, whereas Smad3 is not required. Smad2 target genes
(Mmp2 and Mmp9) are inhibited in SB-431542-treated limbs,
whereas non-canonical TGF-β targets (e.g. Mmp13) are unaffected.
This is the first study to show that Smad2 and Smad3 are differentially
regulated during regeneration and places Smad2 at the heart of
TGF-β signaling supporting the regenerative process.
KEY WORDS: Axolotl, Epimorphic, Regeneration, TGF-β signaling,
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mexicanum
INTRODUCTION
The capacity to regenerate complex tissues and organs as adults is a
process exhibited by few vertebrates. In fact, urodeles (e.g. axolotls
and newts) are the only tetrapods that can regenerate multiple tissues
throughout their life. The urodele limb represents an ideal structure
for understanding the signals modulating the process of epimorphic
regeneration in vertebrates. The stages of limb regeneration are well
characterized (Iten and Bryant, 1973; Tank et al., 1976) and animals
tolerate the surgery extremely well. Limb regeneration represents a
highly orchestrated series of cellular and molecular events that
control cellular migration and proliferation, as well as the initial
wound healing phase. The process is often subdivided into two
general phases: (1) a preparation phase immediately following
amputation, comprising wound epithelium formation, cellular
dedifferentiation, migration and proliferation giving rise to the
blastema; and (2) a redevelopment phase, which is generally
considered to initiate around the late bud stage of blastema
formation and corresponds to when regeneration becomes nerve
independent, cellular redifferentiation starts in parallel with pattern
formation and cells stop proliferating (Tank et al., 1976; Wallace,
1981; Gardiner et al., 1999).
The preparation phase of limb regeneration shares similarities with
mammalian wound healing during the first 48-72 h post-amputation/
wounding (Roy and Lévesque, 2006; Denis et al., 2013). Both are
characterized by the migration of epidermal cells to cover thewound,
the upregulation of extracellular matrix (ECM) remodeling proteins,
the appearance of some inflammatory markers and the activation of
dermal fibroblasts to migrate under the wound epithelium (Yang and
Bryant, 1994; Yang et al., 1999a; Han et al., 2005; Godwin et al.,
2013). To understand howaxolotls can regenerate lost body parts, it is
important to determine which specific molecular pathways of the
normal wound healing response observed in non-regenerating
models are present in this regenerating organism. It is also
important to determine the regulation and function of the different
components of such pathways in a situation of complete regeneration.
A previous study demonstrated that the level of Tgf-β1mRNAwas
upregulated early following amputation (already upregulated at 6 h)
and that expression remained high until early bud stage, when it
returned to normal (Levesque et al., 2007). In that same study, SB-
431542, which is a chemical antagonist of TGF-β receptor type I
(TβR-I) (Inman et al., 2002), was used to specifically inhibit TGF-β
signaling. This demonstrated, for the first time, that TGF-β signaling
is necessary for the cellular proliferation that gives rise to the
blastema and limb regeneration. TGF-β signaling is important during
development, wound healing, bone fracture healing and in
compensatory liver hyperplasia following partial hepatectomy
(Braun et al., 1988; Zentella and Massague, 1992; Massague,
2000; Gabbiani, 2003). Interestingly, TGF-β1 has also been shown to
regulate matrix metalloproteinases (MMPs), tissue inhibitors of
MMPs (TIMPs) (Overall et al., 1991; Sehgal and Thompson, 1999;
Blavier et al., 2001) and fibronectin in several species, including
axolotls (Zhao, 1999; Levesque et al., 2007). The Smad transcription
factors represent the major intracellular mediators of TGF-β
superfamily signaling. There are eight Smads in mammals
(Smad1-8) responsible for transmitting the TGF-β superfamily
response from the cell surface receptors to the nucleus (Massague and
Chen, 2000; Wrana and Attisano, 2000; Attisano and Wrana, 2002;
Derynck and Zhang, 2003). Smads are divided into three types:
receptor Smads (R-Smads), which are phosphorylated by TβR-I; co-
Smad (Smad4), which heterodimerizes with R-Smads to induce
transcription; and inhibitory Smads (I-Smads), which block the
phosphorylation of R-Smads. TGF-βs and BMPs utilize different
subsets of cell surface receptors as well as different Smads to transmit
their signals. The TGF-β isoforms 1-3 signal via R-Smads 2 and 3
and are negatively controlled by I-Smad7. Canonical TGF-β
signaling involves the phosphorylation of two serines in the C-
terminus of both Smad2 and Smad3 by TβR-I (Zhang et al., 1996;
Nakao et al., 1997). BMPs signal via R-Smads 1, 5 and 8 and areReceived 2 October 2015; Accepted 8 August 2016
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negatively controlled by I-Smad6. Smad4 is the co-Smad for all the
R-Smads and is used for TGF-β and BMPs. There are also non-
canonical TGF-β signaling pathways that are mediated via the
mitogen-activated protein kinases, such as p38 and Jun-k, and
phosphatidylinositol-3-kinase/Akt (Zhang, 2009; Mu et al., 2012).
Limb regeneration shares many similarities with limb
development, including the interaction of epithelial and
mesenchymal cells (Neufeld and Aulthouse, 1986). This
interaction requires the absence of a basement membrane between
these two cell types, at least during the initial stages of regeneration.
During limb regeneration, Neufeld and co-workers showed that the
basement membrane was not re-established early during the
regenerative process, allowing interactions between epithelial and
mesenchymal cells (Neufeld and Day, 1996; Neufeld et al., 1996).
The idea that blocking TGF-β signaling leads to the premature
establishment of the basal membrane, thereby preventing the wound
epithelium frombeing permissive, is the first thing thatwe assessed in
the present study. Also, in order to determine how TGF-β controls
limb regeneration, a better understanding of the intracellular
components of the pathway is needed. Various Smad knockout
(KO) mice have been generated: Smad2 and Smad4KOs were lethal,
whereas the Smad3 KO was viable (Nomura and Li, 1998; Sirard
et al., 1998; Waldrip et al., 1998; Weinstein et al., 1998; Zhu et al.,
1998; Datto et al., 1999; Yang et al., 1999b). The phenotype of
Smad3 KO mice was interesting in multiple ways: (1) mice were
viable and relatively normal (Datto and Wang, 2000); (2) the TGF-β
response was somewhat amplified in fibroblasts, which is contrary to
what onewould expect for anR-SmadKO (Piek et al., 2001); (3) they
displayed improved wound healing capacities for various types of
injury, which were marked by an increased rate of re-epithelialization
and significantly reduced scarring (Ashcroft et al., 1999; Flanders
et al., 2003; Falanga et al., 2004); and (4) they had less inflammation
following skin wounding (Ashcroft et al., 1999; Yang et al., 1999b;
Ashcroft and Roberts, 2000). All of these changes observed in the
Smad3 KO mice, as compared with their wild-type littermates,
actually display a striking resemblance to the early phases of
regeneration in axolotls (Roy and Lévesque, 2006). This also
highlights the fact that Smad2 and Smad3 play different roles in
mediating TGF-β signaling. Smad3 is associated with scarring and
the inhibition of proliferation, whereas Smad2 is associated with
cellular migration and proliferation (Brown et al., 2007). These
functions are not simultaneously compatible with the regenerative
process. Scarring is absent during limb regeneration, while
proliferation and cellular migration are necessary during the
preparation phase (Wallace, 1981; Levesque et al., 2007).
The present study focuses on the role of Smad2 and Smad3, as the
mediators of the canonical TGF-β signaling pathway, during the
early phase of limb regeneration in axolotl. Newly available
reagents made it possible to determine whether Smad2 and Smad3
are activated during limb regeneration and to what extent their
individual roles are important in this process.
RESULTS
The basement membrane is not prematurely restored by
TGF-β inhibition
It was previously shown that cellular proliferation is blocked by the
TGF-β antagonist SB-431542 (Levesque et al., 2007). The same
study also showed that 7 days of treatment is enough to prevent
regeneration, even when treatment is then stopped. However, wound
closure was not noticeably affected. Hence, we wondered whether
the basement membrane was restored prematurely in treated
animals, thereby inhibiting signaling between the apical epithelial
cap (AEC) and the underlying mesenchymal cells. This could
explain, in part, the loss in cellular proliferation of mesenchymal
cells observed when TGF-β signaling is blocked. In order to assess
restoration of the basement membrane, we took advantage of
Picrosirius Red staining, which is specific for collagens (Junqueira
et al., 1978, 1979; Kiraly et al., 1997).
Collagens in the basement membrane were not detectable at the
amputated extremity 6 days post-amputation in control or treated
limbs (Fig. 1B,E). To confirm the lack of a basement membrane
under the AEC, the expression of Col IV protein, a specific marker
of basement membrane (Kuhn, 1995; Poschl et al., 2004), was
assessed. As shown in Fig. 1C,C′,F,F′, Col IV is not present under
the AEC site 6 days post-amputation in either controls or SB-
431542-treated animals. Other time points (as shown in Fig. S1)
demonstrated that, even as late as medium bud or palette stage, the
basement membrane is not reformed prematurely in SB-431542-
treated animals. Therefore, the lack of proliferation observed in SB-
431542-treated limbs is not due to the premature formation of
basement membrane.
Cloning of Smad2, Smad3 and Smad7
Since TGF-β signaling is essential for regeneration and blastema
formation, regulation of the intracellular components of the
canonical pathway was assessed. Canonical signaling occurs
through the C-terminal phosphorylation of serine residues of
Smad2 and Smad3. Full-length cDNAs were cloned for Smad2 and
Smad3 (GenBank accessions KT383019 and KT383020), as well as
a partial clone for Smad7 (see the supplementary Materials and
Methods). Of particular interest was the C-terminal portion of
Smad2 and Smad3 that contains the SSVS motif, which is
phosphorylated twice for activation (Massague et al., 2005). The
sequence identity of axolotl proteins compared with human is 99%
(464/467 amino acids) for Smad2 and 93% (402/432 amino acids)
for Smad3, showing that these proteins are highly conserved
(Figs S2 and S3) over a vast phylogenetic distance from urodeles to
humans, spanning 370 million years (Smith and Voss, 2006).
Involvement of Smads and TGF-β signaling in normal
regeneration
RT-PCR and western blotting (Smad2 and Smad3) analyses were
performed to assess the expression of Smads and the
phosphorylation of the Smad C-terminal SSVS motif during
regeneration. Commercially available antibodies were used for all
proteins except for phosphorylated axolotl Smad3 (p-Smad3),
which was not recognized by most commercial antibodies. The
Biorbyt S425 p-Smad3 antibody (orb222846) did cross react with
the axolotl protein but only recognizes one phosphorylation site. An
in-house mouse polyclonal antibody was raised against a 12 amino
acid phospho-peptide identical in sequence to the last 12 amino
acids of the axolotl p-Smad3 protein. No antibodies were found that
cross-reacted against the axolotl Smad7 protein.
The results show that Smad2, Smad3 and Smad7 do not differ
significantly at the mRNA level during the preparation phase of
limb regeneration (Fig. 2A). Expression of Smad2, Smad3 and
Smad7 mRNA did, however, show an upregulation during the
redevelopment phase. The timing of this upregulation correlates
with an accumulation of cells in the regenerative process (Wallace,
1981). Tgf-β2, Activin and Smad4 mRNA levels were not
upregulated (data not shown). Since RT-PCR measures mRNA
levels, findings may correlate with total protein levels but are not
informative regarding potential post-translational modifications.
Indeed, Smad2 and Smad3 are known targets for post-translational
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modifications (e.g. S-phosphorylation at the C-terminus) and these
could play a role in blastema formation. Western blot experiments
looking at total and phosphorylated Smad proteins were conducted.
Results show maximal expression of active TGF-β1 (12.5 kDa
fragment) between 6 h and 48 h (Fig. 2B). Protein expression
matches the mRNA expression of Tgf-β1 described previously
(Levesque et al., 2007). Total Smad2 protein levels were reduced
during the preparation phase but elevated during redevelopment,
which correlates with the RT-PCR results (Fig. 2C).
Phosphorylation of Smad2 was detected between 6 h and 48 h,
which correspond to the time when mesenchymal cells migrate and
begin to proliferate to give rise to the blastema. This also correlates
with maximal expression of active TGF-β1 (Fig. 2C). Total Smad3
protein levels were also reduced during the preparation phase but
elevated during redevelopment, correlating with the RT-PCR results
(Fig. 2D). Phosphorylation of Smad3 was detected from 3 h to 24 h
post-amputation (Fig. 2E-G). Phosphorylation of Smad3 occurs
before phosphorylation of Smad2, while the wound is closing.
Interestingly, detection of p-Smad3 required a very sensitive
reagent, SignalFire Elite ECL Reagent (Cell Signaling), which is
six to seven times more sensitive than the ECL reagent Lumi-
LightPlus (Roche) used to detect p-Smad2 (data not shown).
p-Smad3 was undetectable, or very difficult to detect, with the
reagent used to detect p-Smad2 (Fig. 2C,E). Consequently, the level
of p-Smad3 is likely to be minimal compared with p-Smad2 during
regeneration. These differences were unlikely to be due to the
antibodies used, as our mouse polyclonal and the Biorbyt
commercial antibody yielded identical results. These data suggest
a differential activation of Smad proteins during regeneration.
Inhibition of Smad2 but not Smad3 phosphorylation prevents
regeneration
Activation of Smad proteins is likely to be essential for regeneration,
as treatment with SB-431542 prevents blastema formation and
blocks regeneration (Levesque et al., 2007). SB-431542 is an
inhibitor of TGF-β signaling that acts at the receptor level, thus
preventing phosphorylation of its targets (Smad2 and Smad3). Our
results indeed show a strong inhibition (≥85%) of Smad2
phosphorylation at 24 h post-amputation in animals treated with
25 µM SB-431542 (Fig. 3B,D). Phosphorylation of Smad3 at 3 h
post-amputation is also inhibited (≥53%) when animals are treated
with 25 µM SB-431542 (Fig. 3A,C). Hence, we took advantage of a
second inhibitor, SIS3, which is specific to Smad3 phosphorylation.
Animals were treated with 4 µM, 3 µM and 2 µM SIS3 for 35 days.
Results show that inhibiting Smad3 phosphorylation does not
prevent regeneration. All animals treated with 4 µMSIS3 died before
the end of treatment; however, they all showed a perfectly normal
blastema, as in the size-matched controls (data not shown). Half of
the animals treated with 3 µM SIS3 died after 20 days of treatment,
but again showed blastemas similar to those of control animals at the
time of death. Animals that survived the 35-day treatment
regenerated their limbs to near perfection, with only a few carpal
elements missing in some of the limbs (three of four limbs analyzed
were missing one or two carpal elements) (Fig. 3G,J). No delays in
limb regeneration were observed in animals treated with 2 µM SIS3
(100% survival rate; five out of eight limbs analyzed showed one or
twomissing carpal elements) (Fig. 3F,I). Nevertheless, p-Smad3was
diminished by more than 46% with SIS3 treatment, as assessed by
western blot analysis (Fig. 3C). Smad2 phosphorylation was
unaffected by SIS3 treatment, whereas it was greatly inhibited
following SB-431542 treatment (Fig. 3D). In addition, a third
inhibitor of Smad3, Naringenin, was tested to see whether it would
have the same effects as SIS3. We selected the highest dose that did
not affect the health and growth of animals when treated daily for
35 days (data not shown). When treated with 35 µM Naringenin,
animals regenerated perfectly. p-Smad3, measured 6 h post-
amputation, was reduced by 51%, whereas p-Smad2 levels were
not reduced by Naringenin treatment (data not shown).
Fig. 1. The basement membrane does not prematurely reform when TGF-β signaling is blocked in regenerating axolotl limbs. (A-C′) Control animal,
DMSO treated for 6 days post-amputation. (A,B) Picrosirius Red staining showing normal blastema formation in brightfield view (A) and polarized light (B);
collagen fibers light up red/orange/green. The basement membrane is not restored. (C,C′) Col IV (basement membrane protein) expression (red) confirms that
the basement membrane is not restored (no Col IV is present in the regenerating portion, asterisk). DAPI (blue), showing cell nuclei. C′ is a magnification from C.
(D-F′) Animal treated with 25 µM SB-431542 for 6 days post-amputation. (D,E) Picrosirius Red staining showing no blastema formation (no cells have
accumulated under the wound epidermis) in treated limb in brightfield view (D) and polarized light (E). The basement membrane is not restored. (F,F′) Col IV
expression confirms that the basement membrane is not restored 6 days post-amputation under SB-431542 treatment (no Col IV is present in the regenerating
portion, asterisk). F′ is a magnification from F. Composite images are shown. Arrows indicate the base of the blastema corresponding to the amputation site. n=5
for Picrosirius Red staining; n=3 for Col IV immunofluorescence. Scale bars: 200 µm in A,D; 90 µm in C′,F′.
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In order to clarify further the role of Smad3 in the regenerative
process, we performed electroporation of wild-type and a
phosphomimetic axolotl Smad3 in vivo. We did not observe any
scarring or any effect on the regeneration process (data not shown).
However, the GFP tracer rapidly disappeared when axolotl Smad3
was co-electroporated. We performed TUNEL assays and observed
increased numbers of apoptotic cells (Figs S4 and S5), which would
explain the disappearance of the tracer and the lack of a phenotype,
since cells overexpressing Smad3 are eliminated via apoptosis.
Since limb regeneration is a complex process involving multiple
cell types, we performed immunofluorescence analyses to visualize
the cells that exhibit p-Smad2 and p-Smad3 during regeneration.
p-Smad2 can be observed in epithelial cells and in mesenchymal
cells underneath the wound epithelium in control limbs (Fig. 4B,B′;
see Fig. S6 for additional time points). In SB-431542-treated limbs,
p-Smad2 is very limited (Fig. 4D,D′,E, Fig. S6). Phosphorylation of
Smad3 occurs mostly in epithelial cells and is enriched in thewound
epithelium (Fig. 5B,B′; see Fig. S7 for additional time point). In
SIS3-treated limbs, most cells are negative for p-Smad3 owing to a
decrease in p-Smad3-positive cells of over 85% (Fig. 5D,D′,E,
Fig. S7). The immunofluorescence results for p-Smad2 and
p-Smad3 corresponded exactly to those obtained by western blot
analysis, in that no immunofluorescence signal was detected at
medium bud or palette stage for either protein with or without
SB-431542 treatment (see Fig. S8).
All observations thus far indicate that p-Smad2 is crucial for
blastema formation, whereas p-Smad3 is less important and its
inhibition does not affect regeneration. This further suggests
differential roles of Smad proteins during regeneration.
TGF-β target MMPs are affected by SB-431542, whereas non-
target MMPs are not
TGF-β controls a variety of targets, including genes responsible for
matrix remodeling. In wound healing, matrix remodeling is an
important mechanism in promoting cell migration and cell
proliferation. Cell migration has not been assessed in SB-431542-
Fig. 2. Expression of Smads during normal limb regeneration. (A) Expression of Smad2, Smad3 and Smad7 RNA relative to Gapdh, as assessed by RT-
PCR. Smads are not regulated at the RNA level during the preparation phase (0-96 h post-amputation). Expression increases for all three Smads during the
redevelopment phase (EB-ED). Data show mean±s.e.m., n=3. (B-E) Western blots. (B) Expression of TGF-β1 (12.5 kDa, active form). Maximal expression is
detected during the preparation phase between 6 h and 48 h. (C) Smad2 and p-Smad2 (active form). Activation is maximal between 6 h and 48 h. (D) Expression
of total Smad3 protein. Levels of Smad3 are lower during the preparation phase than the redevelopment phase. (E) p-Smad3 is detected early (3 h post-
amputation), earlier than observed for p-Smad2. (F) Quantification of Smad proteins (densitometric analysis from C-E) during regeneration. (G) Ratio of p-Smad
over total Smad. Maximal activation of Smad3 occurs before maximal activation of Smad2. Welch’s t-test was performed to compare t=0 h with each time point:
***P<0.005, **P<0.01, *P<0.05, +P<0.08. Mean±s.e.m. (normalized using GAPDH, n=4). EB, early bud; MB, medium bud; LB, late bud; Pal, palette; ED, early
differentiation.
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treated limbs, but cellular proliferation is greatly reduced. In
addition, in limbs treated with SB-431542 we do not see any cell
accumulation under the wound epithelium that could result from
either a lack of migration and/or proliferation (Fig. 1D). Therefore,
we performed RT-PCR experiments to assess the effects of SB-
431542 treatment on the expression of TGF-β1 target MMPs and
compare them with other MMPs that are known not to be targets of
TGF-β1. Mmp2 and Mmp9 are known targets of TGF-β. Their
expression is augmented in cancer models (Wiercinska et al., 2011)
and during regeneration (Yang and Bryant, 1994; Yang et al.,
1999a). When treated with SB-431542, the expression of these two
MMPs is diminished (Fig. 6A,B). This could in part explain the lack
of cellular migration and proliferation observed in SB-431542-
treated limbs. The expression of other MMPs (Mmp13 andMmp14)
that are not TGF-β1 targets was not affected by this treatment, at
least not to the same extent (Fig. 6). Mmp14 was reduced slightly
after 5 days of SB-431542 treatment, which is likely to be the result
of indirect effects of TGF-β1 inhibition via p38 and Erk, since this
MMP is not a canonical target of TGF-β (Kuo et al., 2009; Gomes
et al., 2012).
DISCUSSION
Inhibition of TGF-β signaling with SB-431542 does not prevent
wound closure but does prevent blastema formation (Fig. 1)
(Levesque et al., 2007). One possible explanation is that SB-431542
treatment affects signaling between the AEC and underlying
mesenchymal cells. The AEC is a permissive epithelium (Mullen
et al., 1996; Christensen and Tassava, 2000; Han et al., 2001) that is
essential for the regeneration process (Wallace, 1981). In mature
limbs the basement membrane, which is constituted mainly of
collagens, separates epithelial from mesenchymal cells, limiting
their interactions. Following amputation, this structure is absent
from the amputation plane and is not restored completely until the
very end of the regeneration process (Neufeld and Day, 1996;
Neufeld et al., 1996). Premature restoration of this structure could
limit signaling between the AEC and mesenchymal cells, hence
preventing blastema formation. Using collagen-specific histological
staining (Picrosirius Red) and Col IV immunofluorescence we show
that the basement membrane is not restored prematurely upon SB-
431542 treatment. Although TGF-β1 activity is essential for
blastema formation, inhibiting its signaling does not cause
premature restoration of the basement membrane.
Canonical TGF-β signaling occurs via Smad2 and Smad3, which
are phosphorylated by TGF-β type I receptor (ALK5). Recent
studies have revealed functional differences between Smad2 and
Smad3 (Piek et al., 2001; Brown et al., 2007; Ungefroren et al.,
2011). Smad2 has a 30 amino acid insert in the MH1 domain that
prevents direct DNA binding (Brown et al., 2007), whereas Smad3
binds to target sequences in the promoter of genes such as Smad7
(Denissova et al., 2000). Despite its indirect DNA binding, Smad2
Fig. 3. Inhibition of Smad3 phosphorylation hasminimal effect on limb regeneration. (A,B)Western blot. Animals were treated with 25 µMSB-431542, 2 µM
SIS3, or DMSO as control. (A) Proteins were harvested 3 h post-amputation. Blot shows that p-Smad3 is reduced in SB-431542 and in SIS3 treatment
conditions. (B) Proteins were harvested 24 h post-amputation. Smad2 phosphorylation is blocked at 24 h post-amputation by SB-431542 treatment only.
(C) Quantification (from A) shows significant differences between DMSO and inhibitors (SIS3 and SB-431542) for p-Smad3 levels. (D) Quantification (from B)
shows a significant difference between DMSO and SB-431542 but not SIS3 for p-Smad2 levels. (E-J) Ongoing SIS3 treatments with (E,H) DMSO control, (F,I)
2 µM SIS3 or (G,J) 3 µM SIS3 for 35 days. No differences can be observed in brightfield (E-G) and only minor differences can be discerned after Victoria Blue
staining in SIS3-treated limbs (missing carpal or phalange in some limbs) (J). Welch’s t-test was performed to compare protein phosphorylation under different
conditions at 3 h and 24 h: **P<0.01, *P<0.05. Mean±s.e.m. (normalized using GAPDH, n=3).
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is associated with cellular migration and proliferation, while Smad3
is known to control the production of matrix components such as
collagens, the main ECM components implicated in fibrosis/
scarring (Brown et al., 2007). The axolotl Smad2 and Smad3
proteins exhibit very high identity with their human homologs,
indicating that domains of interaction and functions are conserved.
The expression of Smad2, Smad3 and Smad7 mRNA was
determined for all stages of regeneration. Expression of all three
genes is biphasic (Fig. 2), showing low expression during the
preparation phase and an increase during the redevelopment phase.
These upregulation patterns during the redevelopment phase
correlate with an accumulation of cells in the regenerative process
(Wallace, 1981).
Expression of TGF-β1 is maximal between 6 h and 48 h,
correlating with when mesenchymal cells start to migrate under
the AEC, the initial step leading to blastema formation. Normally,
the presence of active TGF-β1 leads to phosphorylation of Smad
proteins. Our results show that p-Smad2 is maximal between 6 h
and 48 h, which correlates perfectly with the presence of active
TGF-β1. Smad2 phosphorylation has been described in other
Fig. 4. SB-431542 prevents phosphorylation of Smad2 in regenerating limbs. (A-B′) Control animal treated for 24 h post-amputation with DMSO.
(A) Hematoxylin and Eosin staining, brightfield image. (B) Nuclei staining (DAPI, blue) overlaid with immunofluorescence of p-Smad2 (red) shows Smad2
phosphorylation in most cells of the wound epithelium and in some underlying mesenchymal cells. (B′) Magnified view from B in the region of the asterisk.
Phosphorylated proteins are often seen in the nucleus (pink, examples indicated with arrows). (C-D′) Animal treated for 24 h post-amputation with 25 µM
SB-431542. (C) Hematoxylin and Eosin staining, brightfield image. (D) Overlay of DAPI and p-Smad2 immunofluorescence shows very few p-Smad2-positive
cells when treated with SB-431542. (D′) Magnified view from D in the region of the asterisk. Composite images are shown in A-D. (E) Quantification (%) of cells
positive for nuclear p-Smad2. Error bars indicate s.e.m. Welch’s t-test was performed to compare protein phosphorylation levels: *P<0.05 (n=5). Scale bars:
200 µm in A,C; 50 µm in B′,D′.
Fig. 5. SIS3 treatment reduces p-Smad3 in regenerating limbs. (A-B′) Control animal treated for 6 h post-amputation with DMSO. (A) Hematoxylin and Eosin
staining, brightfield image. (B) Overlay of nuclei staining (DAPI, blue) and p-Smad3 immunofluorescence (red) shows Smad3 phosphorylation in cells of the
wound epithelium. (B′) Magnified view from B in the region of the asterisk, showing that p-Smad3 is often seen in the nucleus (pink, examples indicated by
arrows). (C-D′) Animal treated for 6 h post-amputation with 5 µMSIS3. (C) Hematoxylin and Eosin staining, brightfield image. (D) Overlay of nuclei staining (DAPI,
blue) and p-Smad3 immunofluorescence (red) shows reduced Smad3 phosphorylation. (D′) Magnified view (in the region of the asterisk in D) showing that
p-Smad3 signal is not localized in the nucleus (arrow). Composite images are shown in A-D. (E) Quantification (%) of cells positive for nuclear p-Smad3. Error
bars indicate s.e.m. Welch’s t-test was performed to compare protein phosphorylation levels: *P<0.05 (n=3). Scale bars: 300 µm in A,C; 60 µm in B′,D′.
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regenerating organisms, such as Xenopus (Ho and Whitman, 2008)
and gecko (Gilbert et al., 2013). In both cases, p-Smad2 is
associated with the wound epithelium. Similarly, our results show
that p-Smad2 is located mostly in the wound epithelium. Ho and
Whitman (2008) reported that p-Smad2 colocalizes with active
TGF-β5 [the Xenopus homolog of mammalian TGFβ1 (Burt and
Law, 1994)], with maximal phosphorylation at 24 h post-wounding.
When TGF-β signaling is impaired with SB-431542, the wound
epithelium fails to form in Xenopus and regeneration does not occur
(Ho and Whitman, 2008). In axolotl limb regeneration, a wound
epithelium is formed following SB-431542 treatment but cellular
proliferation and blastema formation are abrogated (Fig. 1)
(Levesque et al., 2007). These disparities are likely to be due to
the very different doses of SB-431542 used: 25 µM in our study
versus 100 µM in the Ho and Whitman study. We determined the
optimum dose of SB-431542 for use in axolotl, such that
regeneration is inhibited without preventing normal growth or
affecting the health of the animal (Levesque et al., 2007). If axolotls
are treated with 100 µM SB-431542 they do not survive more than
48 h (data not shown) and we deemed it toxic. It is possible that
Xenopus tadpoles can withstand higher doses than axolotls, and if
axolotls could survive at such high concentrations of SB-431542 it
might well prevent wound closure as well. Gilbert et al. (2013)
reported that p-Smad2 is seen throughout tail regeneration in gecko,
specifically in the blastema. The authors propose that activation of
Smad2 is Activin rather than TGF-β1 related. Our PCR results
indicate that Activins and Tgf-β2 are not upregulated during axolotl
limb regeneration (data not shown). Therefore, the Smad2
phosphorylation observed in regenerating axolotl limbs is more
likely to be due to TGF-β1 activity, and the differences observed
between Xenopus, geckos and axolotls are likely to be species-
specific characteristics.
Smad3 activation is associated with scarring in mammals. This
function for Smad3 is supported by the phenotype of Smad3 KO
mice (Ashcroft et al., 1999; Flanders, 2004). p-Smad3 has also been
described in zebrafish heart regeneration. Activation of Smad3 via
Activin/TGF-β in zebrafish heart leads to the formation of a
transient scar that is later resolved to achieve regeneration (Chablais
and Jazwinska, 2012). Treatment with SB-431542 prevents
phosphorylation of Smad3 and hence the heart regeneration
process in zebrafish is inhibited. However, Chablais and Jazwinska
(2012) did not look at p-Smad2 and they did not test Smad3-specific
inhibitors, such as SIS3, to confirm that inhibition of heart
regeneration was due solely to the loss of p-Smad3. In axolotl
limb regeneration, scar formation is never observed (Levesque et al.,
2007, 2010; Denis et al., 2013). We observe low levels of p-Smad3
very early post-amputation (Figs 2 and 5). In addition, specifically
inhibiting Smad3 phosphorylation using SIS3 or Naringenin does
not affect regeneration. Finally, overexpression of Smad3 does not
impair limb regeneration nor does it cause scarring. This is largely
due to the fact that these overexpressing cells are eliminated via
apoptosis (Figs S4 and S5). p-Smad3 is likely to have limited activity
in axolotl limb regeneration (it is detected at very low levels and there
is no effect when inhibited) during the preparation phase. Our study
did look at the levels of p-Smad2 in animals treated with SIS3 and
Naringenin. The results showed clearly that these inhibitors had no
effect on p-Smad2 levels, although they significantly inhibited
Smad3 phosphorylation.
None of the aforementioned studies compared the expression and
activation of Smad2 and Smad3 (Ho and Whitman, 2008; Chablais
and Jazwinska, 2012; Gilbert et al., 2013). Multiple studies have
shown that these two proteins have different functions (Piek et al.,
2001; Petersen et al., 2010; Ungefroren et al., 2011). Our results
show that in regenerating axolotl limbs there is a differential
activation of Smad2 and Smad3. Smad3 is active very early and at
low levels compared with p-Smad2. Specific inhibitors of Smad3
phosphorylation, SIS3 (50% inhibition as assessed by western blot
and over 80% by immunofluorescence) and Naringenin,
significantly reduce the level of p-Smad3 but have no effect on
regeneration. Overexpression of Smad3 does not affect regeneration
either. p-Smad2 is correlated to the active form of TGF-β1 and is
clearly inhibited by treatment with SB-431542. Smad2 inhibition is
Fig. 6. SB-431542 treatment reduces expression of canonical TGF-β target MMPs. Animals were treated for 5 days post-amputation. (A) RT-PCR results.
Animals were treated with DMSO (blue) or 25 µM SB-431542 (red). TGF-β target genes (Mmp2 and Mmp9) are affected by SB-431542 treatment, whereas
non-targets (Mmp13) are not affected or not very much (Mmp14). Welch’s t-test was performed to compare control and treated limbs: ***P<0.005, ** P<0.01,
*P<0.05 (n=5). Mean±s.e.m. (normalized using Gapdh). (B) Agarose gel showing expression of MMP genes and Gapdh after a 5-day treatment with DMSO or
SB-431542. RT–, RT-PCR control without reverse transcriptase.
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strongly correlated with a lack of cellular proliferation and the
absence of blastema formation. Also, Smad7, a known Smad3 target
gene, does not show any increase in expression at the time points
when p-Smad3 is detected, supporting the idea that Smad3
activation is not very strong/important during the early phase of
limb regeneration.
TGF-β1 is known to regulate MMPs (Kahari and Saarialho-Kere,
1997), which are essential during wound healing for matrix
remodeling and proper cell migration. In normal axolotl wound
healing and limb regeneration, the expression of MMP2 and MMP9
has been described (Yang and Bryant, 1994; Yang et al., 1999a;
Seifert et al., 2012). MMPs are also essential for regeneration, since
the broad spectrum inhibitor of MMPs, GM6001, prevents blastema
formation and regeneration (Vinarsky et al., 2005). We show that
following treatmentwith theTGF-β inhibitor SB-431542,MMP2 and
MMP9 are significantly diminished. Interestingly, it was reported that
MMP2 is most likely regulated by Smad2 (Piek et al., 2001; Meng
et al., 2010). Other MMPs, such as MMP13 and MMP14, are not
known to be regulated by the TGF-β canonical signaling pathway
(Johansson et al., 2000; Takahashi et al., 2002; Leivonen et al., 2006)
and are unaffected (MMP13) or only slightly affected (MMP14) by
SB-431542 treatment. Consequently, inhibition of Smad2 activation
correlates with the diminished expression of target MMPs. These
matrix proteases might be essential in providing the proper
environment for mesenchymal cells to migrate, similar to what has
been described in cancer invasion (Wiercinska et al., 2011). Other
MMPs, such as MMP13 and MMP14, might be employed in other
processes such as wound closure or to prevent the basal lamina from
reforming by preventing the deposition of Col IV, which is degraded
by MMP13 (Knauper et al., 1997; Ravanti et al., 1999),
independently of the TGF-β canonical pathway.
This study is the first to examine the activation of the TGF-β
canonical signaling mediators Smad2 and Smad3 in the context of
epimorphic regeneration. It is also the first study to demonstrate that
Smad2 and Smad3 are differentially regulated during regeneration
and that Smad2 activation is essential for axolotl limb regeneration.
The level of p-Smad3 is low compared with that of p-Smad2,
indicating that limb regeneration is controlled by a differential
activation of Smad proteins. Specific inhibition or overexpression of
Smad3 does not affect the regeneration process in axolotl. Treatment
with SB-431542 greatly inhibits the phosphorylation of Smad2 and,
consequently, inhibits regeneration. Treatment with Smad3-specific
inhibitors has no effect on regeneration, even though they achieved
the same level of inhibition as SB-431542. These results suggest
that inhibition of the canonical TGF-β pathway blocks regeneration
by preventing the activation of Smad2.
MATERIALS AND METHODS
Animal maintenance and treatments
Axolotls (Ambystoma mexicanum) were purchased from the Ambystoma
Genetic Stock Center (Lexington, KY, USA) and maintained as described
(Levesque et al., 2007). SB-431542 and SIS3 were purchased from Sigma-
Aldrich. 10 mM stock solutions were prepared in DMSO (Sigma-Aldrich).
After amputation, 4 cm animals were kept in 5 ml and 6 cm animals were
kept in 10 ml 20%Holtfreter’s solution containing 25 µM SB-431542. SIS3
treatments were at 2, 3 or 5 µM. Control animals were treated with DMSO
(same volumes as for SB-431542 and SIS3 compounds). Solutions were
changed daily. Animal care and experiments were performed in accordance
with Université de Montréal Animal Care Committee guidelines.
Production of antibody against axolotl p-Smad3
A peptide corresponding to the phosphorylated C-terminus of axolotl
Smad3 (CGMGTPSLRCSpSVpS) was synthesized (Biomatik) with the
phospho-serine residues corresponding to positions 423 and 425. Peptide
was diluted in sterile PBS at 10 mg/ml. KLH (ThermoFisher Scientific,
77606) was diluted in sterile water at 10 mg/ml for conjugation with the
peptide. Peptide and KLH solutions were mixed and incubated 2 h at room
temperature then stored at −20°C until use. Prior to injection, peptide-KLH
solution was diluted (400 µg/ml peptide) in sterile PBS. Freund’s
incomplete adjuvant (Sigma-Aldrich) was added to a final peptide
concentration of 200 µg/ml. Five 25-day-old BALB/c mice were injected
subcutaneously on the back with this mixture. Booster shots were
administered at 14 days and 28 days. Serum was collected prior to first
injection (pre-serum) and after 10 weeks. Serum was collected in a
microtainer (BD, 365956) and separated following the manufacturer’s
protocol. Western blot analyses were performed to assess the presence of
antibodies against axolotl p-Smad3 in the serum.
RT-PCR
RNA extraction and RT-PCR were performed as described (Levesque et al.,
2007); primers are listed in Table S1. For each non-treated regeneration
stage, two animals of 6 cm (four blastemas) were pooled per preparation for
a total of six animals (n=3 independent replicates). To measure the effect of
SB-431542 on TGF-β1 target genes, animals were treated with 25 µM SB-
431542 or DMSO for 5 days following amputation, two animals of 6 cm
(four blastemas) were pooled per preparation for a total of eight animals
(n=4 independent replicates). For quantification, densitometric analysis was
performed using the AlphaEaseFC (Fluor-Chem 8900) program. Gene
expression was normalized using Gapdh, which has been demonstrated to
be the most appropriate standard during limb regeneration in urodeles
(Vascotto et al., 2005). Relative values are represented compared with t=0 h.
Western blotting
For each non-treated regeneration stage, two animals of 6 cm (four
blastemas) were used per preparation for a total of eight animals (n=4
independent replicates). To measure the effects of SB-431542 and SIS3 on
phosphorylation of Smad2 and Smad3, animals were treated for 3 h or for
24 h following amputation with 25 µM SB-431542, 2 µM SIS3 or DMSO as
a control for the carrier of the drugs. Proteins were extracted by sonication in
Laemmli buffer containing 50 mM NaF. Proteins were quantified using
EZQ Reagent (Invitrogen, R33200) following the manufacturer’s protocol.
30 µg protein was loaded per lane on 10% SDS-PAGE gels. Proteins were
transferred electrophoretically onto Immobilon PVDF membranes
(Millipore, IPVH00010). Antibodies and blotting conditions are described
in Table S2. For quantification, densitometric analysis was performed using
Adobe Photoshop CS4. Protein expression was normalized using GAPDH
and relative values compared with t=0 h (i.e. unamputated control) are
presented.
Picrosirius Red staining
Following treatments with SB-431542 or DMSO, animals were fixed
overnight in 4% paraformaldehyde in 0.7× PBS at 4°C. The following day,
tissues were rinsed thoroughly with 0.7× PBS and embedded in paraffin. To
assess the presence of the basement membrane, 10 µm sections were
rehydrated then stained with Weigert’s Hematoxylin for 10 min, rinsed with
running tap water and then stained with Picrosirius Red (ThermoFisher
Scientific, B21693) for 1 h. Slides were dehydrated and mounted using
Permount (Fisher Scientific). Polarized light was used to visualize collagen
fibers. Slides were visualized with an Axiophot 506747 microscope (Zeiss).
Victoria Blue cartilage staining
Following treatments with SIS3 or DMSO, limbs were stained using
Victoria Blue (Sigma-Aldrich, V-0753) to verify cartilage formation as
previously described (Hutchison et al., 2007). Limbs were fixed in alcoholic
Bouin’s solution for 24 h, then rinsed several times with 70% ethanol.
Limbs were rinsed multiple times with 3.5% NH4OH for 24 h and
then treated with acid alcohol (70% ethanol with 0.4% HCl) for 2 h.
Specimens were stained with 1% Victoria Blue for 2 h and then rinsed with
70% ethanol. Limbs were gradually dehydrated to 100% ethanol, then
cleared and stored in methyl salicylate.
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Apoptosis was assessed by Acridine Orange/ethidium bromide staining or
by TUNEL assay following injection/electroporation (see Table S3) as
described in the supplementary Materials and Methods.
Immunofluorescence enhanced with tyramide
Sections of treated limbs were rehydrated as previously described (Levesque
et al., 2007). Epitope retrieval was performed (1% SDS for 5 min at room
temperature for p-Smad3; and citric acid for 20 min at 95°C for Col IV).
Slideswere blocked using 2%BSA in TBS-T (Tris-buffered salinewith 0.1%
Tween 20) for 1 h at room temperature for p-Smad2 and p-Smad3 or with
Power Block 1× (Hk085.5K, BioGenex) for 15 min at room temperature for
Col IV. Primary antibodies anti-p-Smad2 (3101, Cell Signaling; 1/400) and
anti-p-Smad3 (homemade mouse antibody; 1/500) were diluted in blocking
solution and anti-Col IV (ab6586, Abcam; 1/500) in PBS and incubated
overnight at 4°C. Anti-rabbit-HRP and anti-mouse-HRP (170-6515 and
170-6516, Bio-Rad; 1/400) secondary antibodies were diluted in blocking
solution for p-Smads or PBS for Col IV and incubated at room temperature
for 45 min. Tyramide (Biotium, 92175) was diluted in TBS with 0.0015%
H2O2 to 11.6 µM then incubated at room temperature for 8 min. All slides
were mounted with ProLong Gold antifade reagent containing DAPI
(Invitrogen, 36931). Slides were visualized with a Zeiss Axio Imager M2
optical microscope. The software usedwas Zeiss Zen 2 Pro Blue Edition with
a Tile Module. All images were verified using the range indicator of the
software to ensure that they were not saturated. The images were saved as tif
files and then imported into Photoshop CS4 to adjust the rotation and to crop
to be mounted into a multipanel figure using Adobe Illustrator CS4.
Statistical analysis
Cell counts were performed using ImageJ. Statistical analyses were achieved
using Welch’s t-test, which corrects biases due to an unequal number of
samples and/or variances between the different groups (Scherrer, 2007).
Values are presented as mean±s.e.m.
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